Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Eclipse plunges Guardant into darkness
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
Thermo Fisher flashes the Covid cash
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
